drugset
Drugs / SIIL Live Attenuated Influenza Vaccine
last change Oct 2016 re-read 3 minutes ago

SIIL Live Attenuated Influenza Vaccine

also known as LAIV

Vaccine

Developed for
influenza
Investigated by
Centers for Disease Control and Prevention · Institut Pasteur de Dakar · PATH · Research Institute for Development

Trials 1

today NCT01854632 · Ph 3
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01854632 May → Dec 2013 influenza PATH Completed Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SIIL Live Attenuated Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01854632 ↗
Known as LAIV “This study will provide the Senegal Ministry of Health with data on the clinical efficacy of the Live-Attenuated Influenza Vaccine (LAIV).” NCT01854632 ↗
Modality Vaccine “live attenuated influenza vaccine” NCT01854632 ↗
Route Intranasal “receive a single intranasal dose of masked trivalent live attenuated influenza vaccine or placebo” PMID 27746224 ↗ Oct 2016